Mostrar el registro sencillo del ítem

Cellular and Molecular Aspects of Parkinson Treatment: Future Therapeutic Perspectives

dc.contributor.authorJamebozorgi K.
dc.contributor.authorTaghizadeh E.
dc.contributor.authorRostami D.
dc.contributor.authorPormasoumi H.
dc.contributor.authorBarreto G.E.
dc.contributor.authorHayat S.M.G.
dc.contributor.authorSahebkar A.
dc.date.accessioned2020-09-02T22:20:41Z
dc.date.available2020-09-02T22:20:41Z
dc.date.issued2019
dc.identifier10.1007/s12035-018-1419-8
dc.identifier.citation56, 7, 4799-4811
dc.identifier.issn08937648
dc.identifier.urihttps://hdl.handle.net/20.500.12728/4965
dc.descriptionParkinson’s disease is a neurodegenerative disorder accompanied by depletion of dopamine and loss of dopaminergic neurons in the brain that is believed to be responsible for the motor and non-motor symptoms in this disease. The main drug prescribed for Parkinsonian patients is l-dopa, which can be converted to dopamine by passing through the blood-brain barrier. Although l-dopa is able to improve motor function and improve the quality of life in the patients, there is inter-individual variability and some patients do not achieve the therapeutic effect. Variations in treatment response and side effects of current drugs have convinced scientists to think of treating Parkinson’s disease at the cellular and molecular level. Molecular and cellular therapy for Parkinson’s disease include (i) cell transplantation therapy with human embryonic stem (ES) cells, human induced pluripotent stem (iPS) cells and human fetal mesencephalic tissue, (ii) immunological and inflammatory therapy which is done using antibodies, and (iii) gene therapy with AADC-TH-GCH gene therapy, viral vector-mediated gene delivery, RNA interference-based therapy, CRISPR-Cas9 gene editing system, and alternative methods such as optogenetics and chemogenetics. Although these methods currently have a series of challenges, they seem to be promising techniques for Parkinson’s treatment in future. In this study, these prospective therapeutic approaches are reviewed. © 2018, Springer Science+Business Media, LLC, part of Springer Nature.
dc.language.isoen
dc.publisherHumana Press Inc.
dc.subjectGene therapy
dc.subjectl-dopa
dc.subjectMolecular mechanisms
dc.subjectParkinson’s disease
dc.subjectTransplantation therapy
dc.subject3 (3,4 dihydroxyphenyl)lactic acid
dc.subjectaromatic levo amino acid decarboxylase
dc.subjectaurantiin
dc.subjectbaicalein
dc.subjectcurcumin
dc.subjectdaidzein
dc.subjectepigallocatechin gallate
dc.subjectesculin
dc.subjectgenistein
dc.subjectginkgolide B
dc.subjectginsenoside Rb 1
dc.subjectginsenoside Rd
dc.subjectginsenoside Re
dc.subjectginsenoside Rg 1
dc.subjectguanosine triphosphate cyclohydrolase I
dc.subjecthyperin
dc.subjectisorhynchophylline
dc.subjectlevodopa
dc.subjectmagnolol
dc.subjectpuerarin
dc.subjectquercetin
dc.subjectresveratrol
dc.subjectsalvianolic acid B
dc.subjectstepholidine
dc.subjecttetramethylpyrazine
dc.subjectthymoquinone
dc.subjecttriptolide
dc.subjecttyrosine 3 monooxygenase
dc.subjectumbelliferone
dc.subjectunindexed drug
dc.subjectbiological product
dc.subjectbrain depth stimulation
dc.subjectcell therapy
dc.subjectchemogenetics
dc.subjectCRISPR-CAS9 system
dc.subjectgenetic procedures
dc.subjecthuman
dc.subjecthuman embryonic stem cell
dc.subjectimmunotherapy
dc.subjectmesencephalic tissue
dc.subjectmolecular therapy
dc.subjectmotor performance
dc.subjectnonhuman
dc.subjectnuclear reprogramming
dc.subjectoptogenetics
dc.subjectParkinson disease
dc.subjectpluripotent stem cell
dc.subjectquality of life
dc.subjectReview
dc.subjectRNAi therapeutics
dc.subjectstem cell transplantation
dc.subjecttreatment response
dc.subjectviral gene delivery system
dc.subjectanimal
dc.subjectbiological model
dc.subjectcell transplantation
dc.subjectgene editing
dc.subjectgene therapy
dc.subjectimmunology
dc.subjectParkinson disease
dc.subjectAnimals
dc.subjectBiological Products
dc.subjectCell Transplantation
dc.subjectGene Editing
dc.subjectGenetic Therapy
dc.subjectHumans
dc.subjectModels, Biological
dc.subjectParkinson Disease
dc.titleCellular and Molecular Aspects of Parkinson Treatment: Future Therapeutic Perspectives
dc.typeReview


Ficheros en el ítem

Thumbnail
Nombre:
item_2-s2.0-85056171769.pdf
Tamaño:
4.265Kb
Formato:
PDF
Ver/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem